NCT03478995View on ClinicalTrials.gov

Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

March 16, 2020

Study Completion Date

March 16, 2020

Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
DRUG

GX-I7

GX-I7 25mg/ml/vial

Trial Locations (3)

03722

Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

Unknown

Seoul St. Mary's Hospital, of the Catholic University, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT03478995 - Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter